Evaluation of immune-related response criteria (irRC) in patients (pis) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475

被引：15

作者：

Hodi, F. Stephen

Ribes, Antoni

Daud, Adil

Hamid, Omid

Robert, Caroline

Kefford, Richard

Hwu, Wan-Jan

Gangadhar, Tara C.

Joshua, Anthony M.

Hersey, Peter

Weber, Jeffrey S.

Dronca, Roxana Stefanie

Perrone, Andrea Marie

Gammage, Linda

Mille, Darcy

Xue, Dahai

Kang, Soonmo Peter

Chun, Patrick

Ebbinghaus, Scot

Wolchok, Jedd D.

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[3] Univ Calif San Francisco, San Francisco, CA 94143 USA

[4] Angeles Clin & Res Inst, Los Angeles, CA USA

[5] Inst Gustave Roussy, Paris, France

[6] Univ Sydney, Westmead Hosp, Westmead, NSW 2145, Australia

[7] Univ Sydney, Melanoma Inst Australia, Westmead, NSW 2145, Australia

[8] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[9] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[10] Princess Margaret Canc Ctr, Toronto, ON, Canada

[11] Univ Sydney, Sydney, NSW 2006, Australia

[12] H Lee Moffitt Canc Ctr & Res Inst, Comprehens Melanoma Res Ctr, Tampa, FL USA

[13] Mayo Clin, Dept Med Oncol, Rochester, MN USA

[14] Merck, West Point, PA USA

[15] Merck & Co Inc, West Point, PA USA

[16] Merck & Co Inc, N Wales, PA USA

[17] Merck & Co Inc, Rahway, NJ 07065 USA

[18] Merck MRL, Kenilworth, NJ USA

[19] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.3006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

3006

引用

页数：1